GARFIELD-AF Registry

GARFIELD-AF registry

GARFIELD-AF was the largest prospective registry of patients with newly diagnosed atrial fibrillation

Back to GARFIELD-AF
Keep Up to Date Login
Menu
  • Home

      • The TRI team continues to publish papers based on data accrued during the study (#50 was published in April 2021). Click on a branch of the tree to access the papers associated with that area.

        • Burden of Disease
        • Risk Stratification
        • Treatment Practices
        • Therapy Persistence
        • Clinical Outcomes
        • Geographic Differences
        • Health Economics
  • About
    • About GARFIELD-AF
    • Our Governance
    • About Atrial Fibrillation
    • External Links
  • Risk Calculator
  • Publications & Presentations
  • Newsletters
  • Media
  • Community Page

Geographic Differences

GARFIELD-AF has enrolled 57,262 patients from over 1000 centres across 35 countries including the Americas, Europe, Africa and Asia-Pacific

The global range of patients allows and provides insights into the differences in disease management across the globe.

Key Data:

  • Non-vitamin K antagonist oral anticoagulant (NOAC) uptake worldwide varies greatly
    • 20,000 patients from cohorts 1-3 across Europe showed variations in NOAC uptake ranging from 2.6% to 58.0%
  • Marked differences in AF management were observed in Asia compared with other regions of the world
    • On average, patients in Asia treated with VKA:
      • Were younger (67.1 years) than those in other regions of the world (71.3 years)
      • Had lower CHA2DS2-VASc scores (3.0 versus 3.5) but similar HAS-BLED scores (1.3 versus 1.4)
    • Mean international normalised ratio (INR) was lower in patients from other regions of the world (2.0) compared with those in Asia (2.4)
    • The proportion of time in the therapeutic range (defined as INR 2.0-3.0) was substantially lower in Asia (33.1%) compared with other regions of the world (54.1%)
      • 59.3% of INRs in Asia were <2, compared with 28.2% in other regions of the world
      • 9.6% of INRs in Asia were >3, compared with 17.7% in other regions of the world
  • Use of anticoagulants in Asian patients with a CHA2DS2-VASc score of ≥2 was lower
  • Patients in Asia had a similar incidence of embolic stroke and lower incidences of major bleeding and all-cause mortality, compared with patients in other regions of the world

Key Publications:

Related Publications

Click to view publications related to Geographic Differences... [read more]

16 Jun 21
Previous Page

Community members, please login to view additional information

Global status

Read more
Total patients 57,262
Recruitment Recruitment closed
Follow-up
Study end: 2018

Contact Us

To find out more about GARFIELD-AF, please contact the Thrombosis Research Institute

info@tri-london.ac.uk Contact Us

Follow Us

Keep up to date

Sign up to our newsletter to receive news and updates from us

Keep Up to Date

Funding

The GARFIELD-AF registry was funded by an unrestricted research grant from Bayer AG, and the ongoing work is supported by the Thrombosis Research Institute.

© Copyright TRI 2023

All Rights Reserved. No part of this site may be reproduced without our permission.

  • About TRI
  • Cookie Notice
  • Privacy Policy
  • Terms of Use

Members Login

Coming soon… If you would like to be notified of when this is available click here and add your details to receive updates

Newsletter Signup




    Please see our Privacy Policy and Cookie Policy

    Contact Us

      To find out more about GARFIELD-AF, please contact the Thrombosis Research Institute

      E: garfield@tri-london.ac.uk
      T: 0203 198 9947